CLINICAL TRIALS PROFILE FOR CAPECITABINE

505(b)(2) Clinical Trials for capecitabine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00215982 ↗	Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer	Completed	Roche Pharma AG	Phase 2	2004-12-01	The purpose of this study is to find out how effective the new combination of the drugs Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon and rectal cancer. All three of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of colon or rectal cancer. This however is the first time that these three drugs have been combined in this schedule for the treatment of colon/rectal cancer.
New Combination	NCT00215982 ↗	Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer	Completed	H. Lee Moffitt Cancer Center and Research Institute	Phase 2	2004-12-01	The purpose of this study is to find out how effective the new combination of the drugs Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon and rectal cancer. All three of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of colon or rectal cancer. This however is the first time that these three drugs have been combined in this schedule for the treatment of colon/rectal cancer.
New Combination	NCT00230399 ↗	Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer	Completed	University of Michigan Cancer Center	Phase 2	2003-06-01	This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.
New Combination	NCT00230399 ↗	Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer	Completed	University of Michigan Rogel Cancer Center	Phase 2	2003-06-01	This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.

All Clinical Trials for capecitabine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003704 ↗	Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.
NCT00003704 ↗	Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 1	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.
NCT00003867 ↗	Irinotecan and Capecitabine in Treating Patients With Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	1999-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.
NCT00003867 ↗	Irinotecan and Capecitabine in Treating Patients With Solid Tumors	Completed	Albert Einstein College of Medicine of Yeshiva University	Phase 1	1999-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.

Clinical Trial Conditions for capecitabine

Condition Name

Condition Name for capecitabine
Intervention	Trials
Breast Cancer	256
Colorectal Cancer	187
Gastric Cancer	148
Rectal Cancer	104

Condition MeSH

Condition MeSH for capecitabine
Intervention	Trials
Breast Neoplasms	488
Colorectal Neoplasms	380
Stomach Neoplasms	245
Rectal Neoplasms	237

Clinical Trial Locations for capecitabine

Trials by Country

Trials by Country for capecitabine
Location	Trials
China	937
Japan	419
Italy	405
Taiwan	96
Austria	89

Trials by US State

Trials by US State for capecitabine
Location	Trials
California	245
Texas	214
New York	201
Florida	170
Pennsylvania	156

Clinical Trial Progress for capecitabine

Clinical Trial Phase

Clinical Trial Phase for capecitabine
Clinical Trial Phase	Trials
PHASE4	7
PHASE3	56
PHASE2	155

Clinical Trial Status

Clinical Trial Status for capecitabine
Clinical Trial Phase	Trials
Completed	694
Recruiting	491
Unknown status	211

Clinical Trial Sponsors for capecitabine

Sponsor Name

Sponsor Name for capecitabine
Sponsor	Trials
National Cancer Institute (NCI)	187
Hoffmann-La Roche	138
Fudan University	74

Sponsor Type

Sponsor Type for capecitabine
Sponsor	Trials
Other	2300
Industry	1027
NIH	190

Capecitabine Clinical Trials Update, Market Analysis, and Exclusivity Outlook (FDA, Patents, Generics)

Last updated: May 21, 2026

Capecitabine (Xeloda; fluoropyrimidine prodrug converted to 5-FU in tumor tissue) is an established oncology therapy with broad generic penetration in the U.S. The near-term pipeline and trial activity skew toward new combinations, perioperative strategies, and biomarker-defined populations rather than new standalone caps. From an IP standpoint, practical exclusivity has largely expired in major markets for legacy capecitabine products, shifting competitive risk to incremental formulation and method-of-use patents and to country-specific data exclusivities.

---

What is the current clinical trials landscape for capecitabine in 2025 and 2026?

Capecitabine’s trial footprint remains high because it is used across multiple solid tumors, most prominently breast, colorectal, gastric, and pancreatic settings, often as:

• adjuvant or perioperative chemotherapy
• backbone therapy combined with targeted agents or immuno-oncology drugs
• treatment in metastatic regimens where oral administration matters

Where the activity is concentrated (typical trial design patterns)
Across ongoing and recently updated studies, capecitabine commonly appears in:

• combination arms with biologics or immune checkpoint inhibitors
• dose-dense or schedule-optimized regimens (including metronomic or short-course schedules)
• biomarker-driven cohorts (ESR1/ER status in breast; RAS/BRAF and MSI status in colorectal; HER2 and PD-L1 in gastric)
• escalation/de-escalation strategies to reduce toxicity in perioperative care

Clinical endpoints driving current studies

• pathologic complete response and disease-free survival (perioperative)
• overall survival and progression-free survival (metastatic)
• patient-reported outcomes and hand-foot syndrome management (tolerability)
• pharmacogenomics and therapeutic drug monitoring strategies where used

Key review-style read-through for decision-makers
If you are evaluating capecitabine for licensing or partnership, the highest value trial updates usually come from:

• “capecitabine backbone + new agent” phase 1b/2 expansions
• perioperative regimen optimization that may support label amendments
• subgroup analyses that strengthen payer and guideline adoption

---

Which capecitabine clinical trials are most likely to change the market in 2025-2026?

Highest impact categories (market-moving probability)

1. Perioperative and adjuvant intensification/de-escalation studies
   These can shift standards of care and drive formulary inclusion, particularly if toxicity is reduced without compromising efficacy.

2. Combination regimens with newer oncology agents
   Trials that demonstrate durable responses in biomarker-enriched populations can accelerate uptake and create commercial differentiation even when capecitabine itself is generic.

3. Real-world evidence-adjacent endpoints
   Studies that add patient-reported outcomes and toxicity mitigation can matter when multiple generic options exist.

Practical implication

• For investors and acquirers, the commercial “wedge” is typically not capecitabine monotherapy efficacy. It is label expansion and regimen adoption where capecitabine becomes the oral anchor in a multi-drug standard.

---

How is capecitabine being used across indications, and which cancers drive demand?

Dominant oncology use cases

• Breast cancer: adjuvant/metastatic regimens, including combination chemotherapy and schedule-optimized approaches.
• Colorectal cancer: adjuvant and metastatic settings, often aligned with standard-of-care cytotoxics where oral administration can be operationally favored.
• Gastric/GEJ: capecitabine is a common component of fluoropyrimidine regimens.
• Pancreatic: use varies by regimen choice and setting, with capecitabine-based schedules appearing in selected combinations.

Demand drivers

• clinician familiarity
• oral convenience vs infusional fluoropyrimidines
• ability to pair with multiple partner drugs
• established dosing infrastructure (dose modifications for hand-foot syndrome and diarrhea)

---

What is the global and U.S. market position for capecitabine, including growth expectations?

Market structure reality

• Capecitabine is widely marketed as a generic worldwide. The U.S. pricing pressure is structurally high due to multiple approved ANDAs.
• Growth depends on:
  • volume expansion via label changes and regimen adoption
  • market share within generic cohorts
  • geographic growth where access lags (tender systems and hospital formularies)
  • uptake of oral chemotherapy pathways in outpatient settings

Projection framework used by commercial planning

• Base case: modest volume growth tied to incidence trends and perioperative adoption.
• Upside: meaningful if new regimen trials lead to label expansion in a high-incidence segment.
• Downside: if payer preferences shift toward alternative oral fluoropyrimidines or infusional regimens with clearer survival advantage.

Competitive impact

• When capecitabine is generic, the market behaves like a commodity at the tablet level, while differentiation shifts to:
  • patient support programs
  • specialty distribution execution
  • stability and handling characteristics
  • contract pricing and tender wins

---

How does capecitabine compare with 5-FU and other oral fluoropyrimidines?

Commercial and clinical comparison

• Versus infusional 5-FU: capecitabine reduces infusion burden and can support outpatient pathways.
• Versus other oral agents (where applicable): differentiation often comes down to tolerability, dosing convenience, and evidence alignment with standard-of-care regimens.

Market takeaway

• Even if alternatives exist, capecitabine retains use because evidence is embedded in numerous treatment protocols and clinical workflows.

---

When does capecitabine lose exclusivity in the U.S., and what does that mean for generics?

Exclusivity status (functional outcome)

• The original brand exclusivity for Xeloda has long ended in major markets.
• Current competitive dynamics are dominated by:
  • ANDA approvals
  • patent wind-down outcomes
  • any remaining, narrower formulation or method-of-use patents

Generic entry risk

• For established molecules like capecitabine, the dominant litigation risk is typically not about “first generic entry.” It is about:
  • triggering or defending against follow-on patent claims tied to formulations or specific dosing methods.

---

What patents protect capecitabine today, and how strong is the patent estate?

Patent estate reality for established APIs For a legacy small molecule, the patent landscape typically narrows to:

• formulation-specific patents (composition, excipients, particle size, dissolution profiles)
• manufacturing process patents
• method-of-use or treatment regimens in defined indications
• specific dosing schedules or combination regimens

Strength assessment (how markets interpret it)

• Strong estates are those with enforceable, late-expiring claims that map directly to a generic’s proposed label and formulation.
• For capecitabine, the main commercial effect is that many generics can enter without infringing composition claims, so enforcement often focuses on narrower claims tied to specific instructions.

Actionable monitoring

• Track Orange Book listings and district court filings for any late-expiring claims tied to capecitabine products that still have commercial shelf presence.

---

What is the Orange Book status of capecitabine, and which listings matter for Paragraph IV?

Orange Book usage for strategic decisions Key data to watch include:

• listed active ingredients (capecitabine)
• dosage forms and strengths (tablets)
• patent numbers and expiration dates
• exclusivity types (where applicable)
• whether any patents remain listed late enough to support Paragraph IV challenges

Commercial significance

• For capecitabine, Paragraph IV strategy is often less about creating the first generic market and more about securing label positions and contract shelf wins.

---

What patent litigation affects capecitabine generics, and what settlement terms typically drive entry timing?

Typical litigation pattern

• In established drugs, litigation that matters is the one that blocks:
  • specific ANDA approvals on patent grounds
  • launch timing through injunction threats or settlement-based “carve-outs”

How to interpret outcomes

• Settlement-driven entry dates determine actual launch schedules more than purely theoretical patent life.

Decision-useful lens

• If litigation is quiet, commercial planning assumes near-synchronous generic access.
• If litigation concentrates around formulation or method-of-use claims, launch may be delayed or “skinny-labeled” to avoid infringement.

---

Are any biosimilar risks relevant to capecitabine?

No biosimilar pathway applies. Capecitabine is a small molecule and does not face biosimilar competition dynamics.

---

What formulations and dosing variations are protected by patents for capecitabine?

Formulation patent targets

• composition of matter related to tablet characteristics
• dissolution and bioavailability-related changes
• manufacturing process attributes that could be tied to regulatory equivalence claims

Dosing regimen protection

• method-of-use claims in specified cancers and lines of therapy
• combination regimens and schedules

Market note

• In many jurisdictions, generics can enter with bioequivalent tablets even when narrow regimen claims exist, by aligning product labeling and patient instructions.

---

Which companies are most active in capecitabine manufacturing and generic supply?

Capecitabine has multi-source generic supply across major distributors and labelers. Market outcomes are shaped by:

• inventory strength
• contract pricing
• supply continuity
• ability to meet demand during shortages and tender cycles

---

What generic entry risks exist for capecitabine in major markets?

Primary risk drivers

• manufacturing and quality system constraints during demand spikes
• regulatory inspection outcomes that delay releases
• any late-expiring, enforceable Orange Book patents that could force skinny labels or delayed launches

Low-likelihood risk

• broad, life-of-patent API exclusivity for capecitabine because the practical market authorization has already moved beyond original brand exclusivity.

---

How does capecitabine’s clinical profile translate into payer and hospital adoption?

Payer drivers

• cost per treatment course relative to alternatives
• toxicity management costs (hand-foot syndrome, diarrhea)
• oral administration saves infusion center utilization

Hospital adoption drivers

• adherence feasibility and outpatient workflow
• pharmacy support for dose adjustments and toxicity monitoring
• alignment with existing chemo protocols and order sets

---

Key commercial projection scenarios for capecitabine (volume, price, and share)

Base case

• Stable-to-moderate volume growth
• Ongoing price compression typical for generic multi-source therapies

Upside case

• Label expansion from successful perioperative or combination trials
• Strong uptake in settings where oral fluoropyrimidine is preferred

Downside case

• Competitive shift toward other fluoropyrimidine strategies or regimen changes that reduce capecitabine usage proportionally
• Increased toxicity management burdens from certain combination regimens

---

Key Takeaways

• Capecitabine’s clinical trials emphasis in 2025-2026 is combinations, perioperative strategies, and biomarker-defined cohorts rather than new monotherapy breakthroughs.
• The market is structurally generic. Competitive outcomes depend more on contracting, supply reliability, and label/regimen adoption than on API exclusivity.
• Exclusivity has largely ended in the U.S. The remaining strategic risk is narrow patents (formulation or method-of-use) that can affect labeling or entry timing.
• For business decisions, the highest leverage monitoring targets are ongoing phase 1b/2 combination trials and any resulting label-relevant endpoints that could expand capecitabine’s role.

---

FAQs

1. What is the most common toxicity management strategy for capecitabine in clinical practice?
2. Which cancers have the highest proportion of capecitabine use in standard oncology protocols?
3. How do dose reductions for hand-foot syndrome affect treatment continuity and outcomes?
4. What endpoints in perioperative capecitabine trials most directly support label expansion?
5. How do contract tenders and drug shortages typically influence capecitabine pricing and availability in the U.S.?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (capecitabine). U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Capecitabine studies (search results and record updates for 2025-2026). U.S. National Library of Medicine.